Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entinostat in pediatric recurrent/refractory solid tumors
NCT02780804Phase 1Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2017
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of entinostat in solid tumor, central nervous system tumor and lymphoma, sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose (MTD) or Recommended Phase 2 Dose (R2PD) of Entinostat up to 28 days, Frequency of Adverse Events for Entinostat up to 28 days and 4 more. Started Jan 2017; status: completed.
02
Drugs
entinostat
03
Conditions
solid tumorcentral nervous system tumorlymphoma
Beyond the preview
Go deeper on NCT02780804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02780804.